Asieris Reports P-III Bridging Trial of Hexvix for the Treatment of Bladder Cancer
Shots:
- The company highlighted the P-III bridging clinical trial evaluating the additional detection rate and safety of Hexvix and blue light cystoscopy (BLC) vs white light cystoscopy in 158 patients with NMIBC incl. tumors with stage carcinoma in situ (CIS), Ta, and T1
- The trial met its 1EPs & the results will be presented at upcoming academic conferences. Additionally, the company will submit the results of the study to the NMPA for NDA in the coming months
- Asieris & Photocure ASA collaborated in Jan 2021 to obtain the exclusive registration and commercialization rights of Hexvix in mainland China and Taiwan. The company enhancing its pipeline for genitourinary diseases via R&D and strategic partnerships
Ref: PRNewswire | Image: Asieris
Related News:- Photocure Partner Asieris Report the Completion of Patients Enrollment in P-III Clinical Trial of Hexvix in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
